Erasca, Inc.
ERAS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761918
No open-market purchases or sales by Erasca, Inc. insiders were filed in the last 90 days; 256 institutions reported holding it in 13F filings for Q2 2026, worth $5.13B in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Erasca, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 126
- +19 vs. Q1 2024
- Shares held
- 203.6M
- +131.0M (+180.2%) vs. Q1 2024
- Total value
- $480.6M
- +$330.9M (+221.0%) vs. Q1 2024
- New holders
- 39
- 52 more added
- Sold out
- 20
- 23 more reduced
1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ERAS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 256 | $5.13B |
| Q1 2026 | 225 | $4.39B |
| Q4 2025 | 154 | $815.7M |
| Q3 2025 | 141 | $468.5M |
| Q2 2025 | 142 | $277.1M |
| Q1 2025 | 154 | $307.3M |
| Q4 2024 | 146 | $579.5M |
| Q3 2024 | 132 | $633.4M |
| Q2 2024 | 126 | $480.6M |
| Q1 2024 | 108 | $149.7M |
| Q4 2023 | 119 | $147.5M |
| Q3 2023 | 109 | $140.4M |
| Q2 2023 | 112 | $205.2M |
| Q1 2023 | 118 | $234.9M |
| Q4 2022 | 107 | $343.9M |
| Q3 2022 | 88 | $627.9M |
| Q2 2022 | 89 | $428.3M |
| Q1 2022 | 82 | $626.6M |
| Q4 2021 | 63 | $988.0M |
| Q3 2021 | 55 | $919.8M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Erasca, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Goldman Sachs Group Inc | 2,192,636 | $5.17M | 0.00% | +610,620+38.6% | Added |
| State Street Corp | 2,458,180 | $5.80M | 0.00% | +787,495+47.1% | Added |
| Affinity Asset Advisors, LLC | 2,499,431 | $5.90M | 0.93% | +2,499,431 | New |
| Prosight Management, LP | 2,750,000 | $6.49M | 1.94% | −909,755−24.9% | Reduced |
| AH Capital Management, L.L.C. | 2,862,500 | $6.76M | 0.58% | 00.0% | Unchanged |
| Sio Capital Management, LLC | 2,874,536 | $6.78M | 2.56% | +447,352+18.4% | Added |
| Citadel Advisors LLC | 3,293,371 | $7.77M | 0.01% | +2,456,057+293.3% | Added |
| Geode Capital Management, LLC | 3,311,891 | $7.82M | 0.00% | +1,420,348+75.1% | Added |
| Marshall Wace, LLP | 3,672,375 | $8.67M | 0.01% | +3,672,375 | New |
| Woodline Partners LP | 4,134,036 | $9.76M | 0.09% | +3,243,243+364.1% | Added |
| Balyasny Asset Management LLC | 4,319,484 | $10.2M | 0.03% | +4,319,484 | New |
| PFM Health Sciences, LP | 4,671,774 | $11.0M | 0.60% | +2,136,672+84.3% | Added |
| 5AM Venture Management, LLC | 5,405,404 | $12.8M | 2.85% | +5,405,404 | New |
| Logos Global Management LP | 5,900,000 | $13.9M | 1.60% | +5,900,000 | New |
| Vivo Capital, LLC | 6,756,756 | $15.9M | 1.47% | +6,756,756 | New |
| Paradigm Biocapital Advisors LP | 7,250,000 | $17.1M | 0.65% | +7,250,000 | New |
| T. Rowe Price Investment Management, Inc. | 7,374,359 | $17.4M | 0.01% | +7,374,359 | New |
| Silverarc Capital Management, LLC | 7,816,926 | $18.4M | 4.55% | +7,593,081+3,392.1% | Added |
| Janus Henderson Group PLC | 8,178,092 | $19.3M | 0.01% | +8,178,092 | New |
| Artal Group S.A. | 9,630,810 | $22.7M | 0.58% | +4,909,616+104.0% | Added |
| Vanguard Group Inc | 10,351,746 | $24.4M | 0.00% | +6,013,638+138.6% | Added |
| BlackRock Inc. | 10,611,346 | $25.0M | 0.00% | +3,630,176+52.0% | Added |
| ARCH Venture Management, LLC | 11,055,554 | $26.1M | 9.81% | 00.0% | Unchanged |
| Suvretta Capital Management, LLC | 13,768,039 | $32.5M | 1.33% | +13,768,039 | New |
| VR Adviser, LLC | 16,216,216 | $38.3M | 2.44% | +16,216,216 | New |
| Frazier Life Sciences Management, L.P. | 16,216,216 | $38.3M | 1.79% | +16,216,216 | New |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −6,172,000−100.0% | Sold out |
| Schroder Investment Management Group | 0 | $0 | 0.00% | −1,926,000−100.0% | Sold out |
| CVI Holdings, LLC | 0 | $0 | 0.00% | −1,456,311−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −346,953−100.0% | Sold out |
| IPG Investment Advisors LLC | 0 | $0 | 0.00% | −207,470−100.0% | Sold out |
| Pale Fire Capital SE | 0 | $0 | 0.00% | −111,906−100.0% | Sold out |
| Denali Advisors LLC | 0 | $0 | 0.00% | −91,200−100.0% | Sold out |
| American International Group, Inc. | 0 | $0 | 0.00% | −39,768−100.0% | Sold out |
| Algert Global LLC | 0 | $0 | 0.00% | −27,640−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −18,638−100.0% | Sold out |
| CI Private Wealth, LLC | 0 | $0 | 0.00% | −14,555−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −13,300−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −10,407−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −9,565−100.0% | Sold out |
| Point72 (DIFC) Ltd | 0 | $0 | 0.00% | −7,420−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −1,551−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −1,528−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −1,251−100.0% | Sold out |
| GPS Wealth Strategies Group, LLC | 0 | $0 | 0.00% | −350−100.0% | Sold out |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −18−100.0% | Sold out |
| Shell Asset Management Co | – | – | – | – | Not filed |